Abstract
Alendronate is a widely used bisphosphonate in the treatment of osteoporosis. Although it has been proven to be a very useful drug, it has some side effects as well. In this paper, we describe a case of nephrotic syndrome due to alendronate administration. A 36-year-old man was admitted to the nephrology outpatient clinic with widespread edema 4 months after initiation of alendronate. He had a 13-kg weight gain within a 2-week period. He had no clinical or laboratory problems apart from osteoporosis, which was the indication for initiation of the drug. Physical examination at admission was unremarkable, but for nephrotic edema. Laboratory studies revealed nephrotic range proteinuria (13.5 g/day), normal renal function, hypoalbuminemia (1.7 g/dl), and also hypercholesterolemia (400 mg/dl). A kidney biopsy was performed. Light microscopic evaluation revealed a slight increase in mesangial cells and matrix; however, no abnormalities in the tubules or interstitium were noted. Alendronate was withdrawn and diuretic therapy was initiated. Patient’s weight gradually decreased from 84 to 67 kg within a 1-week period. No other drugs for the treatment of nephrotic syndrome were administered. During the clinical course, serum creatinine remained stable, and proteinuria gradually decreased and disappeared 40 days after stopping alendronate. It was noted that alendronate administration can give rise to nephrotic syndrome, while discontinuation of this drug may improve the pathology without any specific treatment.
References
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC (2000) Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88:2961–2978
Cardwell CR, Abnet CC, Cantwell MM, Murray LJ (2010) Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA 304:657–663
Mundel P, Shankland SJ (2002) Podocyte biology and response to injury. J Am Soc Nephrol 13:3005–3015
Kerjaschki D (2001) Caught flat-footed: podocyte damage and the molecular bases of focal glomerulosclerosis. J Clin Investig 108:1583–1587
Miura N, Mizuno N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, Imai H (2009) Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol 13:85–88
Pascual J, Torrealba J, Myers J, Tome S, Samaniego M, Musat A, Djamali A (2007) Collapsing focal segmental glomerulosclerosis in a liver transplant recipient on alendronate. Osteoporos Int 18:1435–1438
Stratton JD, Warwicker P (2002) Relapse of nephrotic syndrome triggered by biphosphonates. Nephrol Dial Transplant 17:1856–1857
Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, Walker PD (2004) Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 65:634–641
Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D’Agati VD (2001) Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164–1172
Tanvetyanon T, Stiff PJ (2006) Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 17:897–907
Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D (2003) Short-term, high dose pamidronate-induced acute tubular necrosis: the postulated mechanisms of bisphosphonate nephrotoxicity. Am J Kidney Dis 41:1–6
Janssen van Doorn K, Neyns B, Van der Niepen P, Verbeelen D (2001) Pamidronate-related nephrotoxicity (tubulointerstitial nephritis) in a patient with osteolytic bonemetastases. Nephron 89:467–468
Bounameaux HM, Schifferli J, Montani JP, Jung A, Chatelanat F (1983) Renal failure associated with intravenous diphosphonates. Lancet 1:471
Buysschaert M, Cosyns JP, Barreto L, Jadoul M (2003) Pamidronate-induced tubulointerstitial nephritis with Fanconi syndrome in a patient with primary hyperparathyroidism. Nephrol Dial Transplant 18:826–829
Yates AJ, Percival RC, Gray RE, Atkins RM, Urwin GH, Hamdy NA, Preston CJ, Beneton MN, Russell RG, Kanis JA (1985) Intravenous clodronate in the treatment and retreatment of Paget’s disease of bone. Lancet 1:1474–1477
Dumon JC, Magritte A, Body JJ (1991) Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 15:257–266
Khosla S (2010) Update in male osteoporosis. J Clin Endocrinol Metab 95:3–10
Acknowledgments
Electron microscopic study was performed at Histology Department of Istanbul University, Istanbul Medical School. The authors thank Dr. Seyhun Solakoglu for performing electron microscopic examination.
Conflicts of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yilmaz, M., Taninmis, H., Kara, E. et al. Nephrotic syndrome after oral bisphosphonate (alendronate) administration in a patient with osteoporosis. Osteoporos Int 23, 2059–2062 (2012). https://doi.org/10.1007/s00198-011-1836-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-011-1836-2